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Monocyte and macrophage phenotypes: a look 
beyond systemic sclerosis
We read with interest the new data from Lescoat et al and their 
interesting comments concerning our research letter on the iden-
tification of circulating cells coexpressing M1 and M2 phenotype 
markers in patients affected by systemic sclerosis (SSc) compared 
with healthy subjects (HSs).1 2
In their study, Lescoat et al evaluated the mean of fluores-
cence intensity of specific markers of M1 and M2 phenotypes 
(CD80, CD206, CD204, CD163, CD169 and CD200R1) in 
macrophage colony-stimulating factor (M-CSF) resting blood 
monocyte-derived-macrophages (MDMs) from HSs exposed to 
in vitro stimuli aiming to polarise them towards the M1, M2a 
and M2c phenotypes. The markers were also evaluated on the 
cell surface of the MDMs obtained from 11 to 16 SSc patients 
not treated with glucocorticoids and compared with those 
obtained from 13 HSs.1 The important conclusion highlighted 
is cultured circulating MDMs from patients with SSc showcells 
with a mixed M1/M2 signature, supporting our results.2
We will soon be able to complement these data with the 
clinical implications seen in a new study that is going to 
demonstrate, in patients with SSc, how the higher percent-
ages of circulating cells showing a mixed M1/M2 phenotype 
correlate significantly with important SSc clinical complica-
tions, such as functional and structural lung damage (data 
under publication).
Lescoat et al appropriately asserted that the results showing 
a mixed phenotype of circulating monocyte/macrophage 
cells in patients with SSc might arise both methodolog-
ical and conceptual questions with respect to the M1/ M2 
definition.
Lescoat’s results further highlighted how macrophages can 
evolve to exhibit characteristics that are shared by more than 
one macrophage population, similarly to secondary colours in 
a colour wheel, as postulated by Mosser and Edwards.3
Although it is true that our study was conducted on circu-
lating and theoretically less differentiated cells, it is also 
possible to hypothesise that the in vitro differentiation of 
monocytes through the stimulation with M-CSF as well as 
GM-CSF probably does not fully reproduce the process 
induced by the in vivo microenvironmental signals.4 5 Also, the 
comparison with cultured macrophages differentiated from 
human cell lines, such as primarily PMA-treated THP-1 cell 
line, would be even less accurate.6
Furthermore, the higher percentages of differentiated and 
activated myeloid-derived circulating cells in patients with SSc 
compared with HSs make part of the most interesting results 
of our research. Our data and those from Lescoat et al could in 
any case coexist, without being in contrast with the different 
findings observed at tissue level, that is, in internal organs 
affected by SSc, since the different tissues are able to direct 
the inflammatory response in a proinflammatory direction or 
towards resolution and repair, determining the expression of a 
more polarised and stable cell phenotype in the periphery (ie, 
M1 and/or M2).7
Nevertheless, the more differentiated phenotype observed 
at the tissue level could not mirror the one observed in circu-
lating monocyte/macrophage precursors or that derived from 
in vitro MDMs. Additionally, it was very recently demon-
strated that different cell phenotypes could be observed in 
different tissues especially in SSc and, particularly for innate 
immune cells, given their plasticity.4 5 8
Finally, the acquisitions on monocyte/macrophage polarisa-
tion have shown at least that the approach based on the eval-
uation of single or few markers for the determination of a cell 
signature is no longer conceivable. In fact, the strong interest 
currently found in the contribution of the innate immune cells 
to pathogenic processes should probably be directed towards 
the clarification of the relationships between the phenotype of 
circulating cells and that of more differentiated ones observed 
in peripheral tissues and to a wider phenotype study and 
definition.
The results described in our study and that presented by 
Lescoat et al contributed to identify possible new cell players 
involved in the pathophysiology of SSc.
In accordance with Behmoaras and Petretto, the ques-
tion regarding whether and how the circulating mixed M1/
M2 cells described in our study and/or the MDMs investi-
gated in vitro by Lescoat et al could reflect the context-spe-
cific activation of macrophages in the different SSc tissues 
(ie, lung and skin) remains open and matter of our further 
research.4
Starting from these results, the functional role of mixed 
M1/M2 cells in the pathogenesis of SSc and in other fibrotic 
diseases, as well as the possible effects of modulators and the 
related clinical complications, should be better addressed.1 5 9 
These considerations on the innate immune cell plasticity could 
apply to the contribution to SSc pathogenesis and to other 
fibrotic diseases and pathological or even physiological 
conditions.7
Maurizio Cutolo, Amelia Chiara Trombetta, Stefano Soldano
Research Laboratory and Academic Division of Clinical Rheumatology, Department 
of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino Hospital, 
Genoa, Italy
Correspondence to Professor Maurizio Cutolo , Research Laboratory and 
Academic Division of Clinical Rheumatology, Department of Internal Medicine, 
University of Genova, Polyclinic San Martino Hospital, Genoa 16132, Italy ;  
 mcutolo@ unige. it
Handling editor Josef S Smolen
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.
© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and 
permissions. Published by BMJ.
MC, ACT and SS contributed equally.
To cite Cutolo M, Trombetta AC, Soldano S. Ann Rheum Dis Epub ahead of print: 
[please include Day Month Year]. doi:10.1136/annrheumdis-2018-214371
Received 7 September 2018
Accepted 7 September 2018
 ► https:// doi. org/ 10. 1136/ annrheumdis- 2018- 214333
Ann Rheum Dis 2018;0:1–2. doi:10.1136/annrheumdis-2018-214371
RefeRences
 1 Lescoat A, Ballerie A, Jouneau S. M1/M2 polarization state of M-CSF blood-
derived macrophages in Systemic sclerosis. Ann Rheum Dis 2018. doi:10.1136/
annrheumdis-2018-214333. [Epub ahead of print]. 
Correspondence response
 o
n
 29 July 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214371 on 29 Septem
ber 2018. Downloaded from
 
2 Ann Rheum Dis Month 2018 Vol 0 No 0
Correspondence response
 2 Soldano S, Trombetta AC, Contini P, et al. Increase in circulating cells coexpressing M1 
and M2 macrophage surface markers in patients with systemic sclerosis. Ann Rheum 
Dis 2018. doi:10.1136/annrheumdis-2018-213648. [Epub ahead of print].
 3 Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev 
Immunol 2008;8:958–69.
 4 Behmoaras J, Petretto E. Cell function in disease: there are more than two parties at 
play. Ann Rheum Dis 2018. doi:10.1136/annrheumdis-2018-213121. [Epub ahead of 
print].
 5 Moreno-Moral A, Bagnati M, Koturan S, et al. Changes in macrophage transcriptome 
associate with systemic sclerosis and mediate GSDMA contribution to disease risk. Ann 
Rheum Dis 2018;77:596–601.
 6 Forrester MA, Wassall HJ, Hall LS, et al. Similarities and differences in surface receptor 
expression by THP-1 monocytes and differentiated macrophages polarized using seven 
different conditioning regimens. Cell Immunol 2018;332:58–76.
 7 Matzinger P, Kamala T. Tissue-based class control: the other side of tolerance. Nat Rev 
Immunol 2011;11:221–30.
 8 Taroni JN, Greene CS, Martyanov V, et al. A novel multi-network approach reveals 
tissue-specific cellular modulators of fibrosis in systemic sclerosis. Genome Med 
2017;9:27.
 9 Soldano S, Pizzorni C, Paolino S, et al. Correction: alternatively activated (M2) 
macrophage phenotype Is inducible by endothelin-1 in cultured human macrophages. 
PLoS One 2017;12:e0175238.
 o
n
 29 July 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214371 on 29 Septem
ber 2018. Downloaded from
 
